How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    4 Proposed date for review of guidance

    4.1 NICE proposes that the guidance on this technology is considered for review 3 years after publication of the guidance. NICE welcomes comment on this proposed date. NICE will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

    Jane Adam
    Chair, appraisal committee A
    March 2022